12 results on '"Delafontaine, Patrice"'
Search Results
2. Ct Values Do Not Predict Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmissibility in College Students.
- Author
-
Tian D, Lin Z, Kriner EM, Esneault DJ, Tran J, DeVoto JC, Okami N, Greenberg RM, Yanofsky S, Ratnayaka S, Tran N, Livaccari M, Lampp ML, Wang N, Tim S, Norton P, Scott J, Hu TY, Garry R, Hamm L, Delafontaine P, and Yin XM
- Subjects
- COVID-19 epidemiology, Carrier State virology, Contact Tracing, Female, Humans, Louisiana epidemiology, Male, Nasopharynx virology, Public Health, Quarantine, Retrospective Studies, Students statistics & numerical data, Viral Load, Young Adult, COVID-19 transmission, COVID-19 virology, COVID-19 Nucleic Acid Testing methods, Multiplex Polymerase Chain Reaction methods, Universities statistics & numerical data
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly contagious and has caused significant medical/socioeconomic impacts. Other than vaccination, effective public health measures, including contact tracing, isolation, and quarantine, is critical for deterring viral transmission, preventing infection progression and resuming normal activities. Viral transmission is affected by many factors, but the viral load and vitality could be among the most important ones. Although in vitro studies have indicated that the amount of virus isolated from infected individuals affects the successful rate of virus isolation, whether the viral load carried at the individual level would determine the transmissibility was unknown. We examined whether the cycle threshold (Ct) value, a measurement of viral load by RT-PCR assay, could differentiate the spreaders from the non-spreaders in a population of college students. Our results indicate that while at the population level the Ct value is lower, suggesting a higher viral load, in the symptomatic spreaders than that in the asymptomatic non-spreaders, there is a significant overlap in the Ct values between the two groups. Thus, Ct value, or the viral load, at the individual level could not predict the transmissibility. Instead, a sensitive method to detect the presence of virus is needed to identify asymptomatic individuals who may carry a low viral load but can still be infectious., (Copyright © 2021 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
3. TRAF3IP2 mediates atherosclerotic plaque development and vulnerability in ApoE(-/-) mice.
- Author
-
Sakamuri SSVP, Higashi Y, Sukhanov S, Siddesha JM, Delafontaine P, Siebenlist U, and Chandrasekar B
- Subjects
- Animals, Atherosclerosis, Collagen metabolism, Crosses, Genetic, Extracellular Matrix metabolism, Female, Gene Deletion, Genotype, Inflammation, Lipoproteins blood, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, ApoE, Necrosis, Sex Factors, Triglycerides blood, Adaptor Proteins, Signal Transducing genetics, Plaque, Atherosclerotic genetics
- Abstract
Background and Aims: Atherosclerosis is a major cause of heart attack and stroke. Inflammation plays a critical role in the development of atherosclerosis. Since the cytoplasmic adaptor molecule TRAF3IP2 (TRAF3-Interacting Protein 2) plays a causal role in various autoimmune and inflammatory diseases, we hypothesized that TRAF3IP2 mediates atherosclerotic plaque development., Methods: TRAF3IP2/ApoE double knockout (DKO) mice were generated by crossing TRAF3IP2(-/-) and ApoE(-/-) mice. ApoE(-/-) mice served as controls. Both DKO and control mice were fed a high-fat diet for 12 weeks. Plasma lipids were measured by ELISA, atherosclerosis by en face analysis of aorta and plaque cross-section measurements at the aortic valve region, plaque necrotic core area, collagen and smooth muscle cell (SMC) content by histomorphometry, and aortic gene expression by RT-qPCR., Results: The plasma lipoprotein profile was not altered by TRAF3IP2 gene deletion in ApoE(-/-) mice. While total aortic plaque area was decreased in DKO female, but not male mice, the plaque necrotic area was significantly decreased in DKO mice of both genders. Plaque collagen and SMC contents were increased significantly in both female and male DKO mice compared to respective controls. Aortic expression of proinflammatory cytokine (Tumor necrosis factor α, TNFα), chemokine (Chemokine (C-X-C motif) Ligand 1, CXCL1) and adhesion molecule (Vascular cell adhesion molecule 1, VCAM1; and Intercellular adhesion molecule 1, ICAM1) gene expression were decreased in both male and female DKO mice. In addition, the male DKO mice expressed markedly reduced levels of extracellular matrix (ECM)-related genes, including TIMP1 (Tissue inhibitor of metalloproteinase 1), RECK (Reversion-Inducing-Cysteine-Rich Protein with Kazal Motifs) and ADAM17 (A Disintegrin And Metalloproteinase 17)., Conclusions: TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability, possibly by inducing the expression of multiple proinflammatory mediators. TRAF3IP2 could be a potential therapeutic target in atherosclerotic vascular diseases., Competing Interests: The authors declared that they do not have anything to disclose regarding conflict of interest with respect to this manuscript., (Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
4. Mechanisms of Cachexia in Chronic Disease States.
- Author
-
Yoshida T and Delafontaine P
- Subjects
- Angiotensin II metabolism, Animals, Cell Proliferation, Cytokines metabolism, Humans, Muscle Proteins metabolism, Muscles pathology, Muscular Atrophy pathology, Oxidative Stress, Proteasome Endopeptidase Complex metabolism, Proteins metabolism, Regeneration, Renin-Angiotensin System drug effects, Signal Transduction, Ubiquitin chemistry, Cachexia therapy, Chronic Disease therapy
- Abstract
Sarcopenia and cachexia are muscle wasting syndromes associated with aging and with many chronic diseases, such as congestive heart failure (CHF), diabetes, cancer, chronic obstructive pulmonary disease and chronic kidney disease (CKD). While mechanisms are complex, these conditions are often accompanied by elevated angiotensin II (Ang II). Patients with advanced CHF or CKD often have increased Ang II levels and cachexia, and angiotensin-converting enzyme inhibitor treatment improves weight loss. It was found that Ang II infusion in rodents leads to skeletal muscle wasting. Ang II increases cytokines and circulating hormones, such as tumor necrosis factor-α, interleukin-6, serum amyloid-A and glucocorticoids, which regulate muscle protein synthesis and degradation. Ang II-induced muscle wasting is caused by alterations in insulin-like growth factor-1 signaling, enhanced muscle protein breakdown via the ubiquitin-proteasome system and decreased appetite resulting from the downregulation of hypothalamic orexigenic neuropeptides, such as Npy and orexin. Ang II also inhibits 5' adenosine monophosphate-activated protein kinase activity and disrupts normal energy balance via the activation of 5' adenosine monophosphate-activated protein kinase phosphatase PP2Cα. Furthermore, Ang II inhibits skeletal muscle stem (satellite) cell proliferation, leading to lowered muscle regenerative capacity. Distinct satellite cell angiotensin receptor subtypes have different effects on different stages of differentiation and are critical for the regulation of muscle regeneration. These data suggest that the renin-angiotensin system plays a critical role in mechanisms underlying cachexia in chronic disease states, and it is a promising target for the treatment of muscle atrophy in patients with diseases such as CHF and CKD.
- Published
- 2015
- Full Text
- View/download PDF
5. Insulin-like growth factor I reduces lipid oxidation and foam cell formation via downregulation of 12/15-lipoxygenase.
- Author
-
Sukhanov S, Snarski P, Vaughn C, Lobelle-Rich P, Kim C, Higashi Y, Shai SY, and Delafontaine P
- Subjects
- Animals, Apolipoproteins E deficiency, Apolipoproteins E genetics, Arachidonate 12-Lipoxygenase genetics, Arachidonate 15-Lipoxygenase genetics, Atherosclerosis blood, Atherosclerosis enzymology, Atherosclerosis genetics, Atherosclerosis pathology, Cell Line, Disease Models, Animal, Dose-Response Relationship, Drug, Down-Regulation, Foam Cells enzymology, Foam Cells pathology, Gene Expression Regulation, Enzymologic, Lipoproteins, LDL blood, Macrophages, Peritoneal enzymology, Macrophages, Peritoneal pathology, Mice, Inbred C57BL, Mice, Knockout, Phosphatidylinositol 3-Kinase metabolism, RNA, Messenger metabolism, STAT6 Transcription Factor metabolism, Signal Transduction drug effects, Arachidonate 12-Lipoxygenase metabolism, Arachidonate 15-Lipoxygenase metabolism, Atherosclerosis prevention & control, Foam Cells drug effects, Insulin-Like Growth Factor I administration & dosage, Lipoproteins, LDL metabolism, Macrophages, Peritoneal drug effects
- Abstract
Objective: We have shown that insulin-like growth factor I (IGF-1) infusion in Apoe(-/-) mice decreased atherosclerotic plaque size and plaque macrophage and lipid content suggesting that IGF-1 suppressed formation of macrophage-derived foam cells. Since 12/15-lipoxygenase (12/15-LOX) plays an important role in OxLDL and foam cell formation, we hypothesized that IGF-1 downregulates 12/15-LOX, thereby suppressing lipid oxidation and foam cell formation., Approach and Results: We found that IGF-1 decreased 12/15-LOX plaque immunopositivity and serum OxLDL levels in Apoe(-/-) mice. IGF-1 reduced 12/15-LOX protein and mRNA levels in cultured THP-1 macrophages and IGF-1 also decreased expression of STAT6 transcription factor. IGF-1 reduction in macrophage 12/15-LOX was mediated in part via a PI3 kinase- and STAT6-dependent transcriptional mechanism. IGF-1 suppressed THP-1 macrophage ability to oxidize lipids and form foam cells. IGF-1 downregulated 12/15-LOX in human blood-derived primary macrophages and IGF-1 decreased LDL oxidation induced by these cells. IGF-1 reduced LDL oxidation and formation of foam cells by wild type murine peritoneal macrophages, however these effects were completely blocked in 12/15-LOX-null macrophages suggesting that the ability of IGF-1 to reduce LDL oxidation and foam cells formation is dependent on its ability to downregulate 12/15-LOX., Conclusions: Overall our data demonstrate that IGF-1 reduces lipid oxidation and foam cell formation via downregulation of 12/15-LOX and this mechanism may play a major role in the anti-atherosclerotic effects of IGF-1., (Published by Elsevier Ireland Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
6. Endovascular stent-graft repair of ascending aortic dissection with a commercially available thoracic endograft.
- Author
-
Atianzar K, Mohamad A, Galazka P, Keller VA, Delafontaine P, and Sam AD 2nd
- Subjects
- Aged, Humans, Male, Aortic Dissection surgery, Aortic Aneurysm, Thoracic surgery, Endovascular Procedures, Stents
- Abstract
We describe the endovascular treatment of a type A thoracic aortic dissection (TAAD) in a patient deemed unfit for surgical repair with a commercially available thoracic endograft. A patient with a symptomatic acute TAAD, multiple medical comorbidities, and ascending thoracic aortic and arch dilation underwent successful endovascular repair with the use of a commercially available stent graft, resulting in complete resolution of his symptoms despite slight but persistent perigraft false lumen perfusion. Although surgical repair remains the gold standard, endografting has promise and may have a positive impact on the current treatment algorithm for TAAD. Advances must occur in graft manufacturing, and further data will be required before wider application is appropriate., (Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
7. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia.
- Author
-
Yoshida T, Tabony AM, Galvez S, Mitch WE, Higashi Y, Sukhanov S, and Delafontaine P
- Subjects
- Animals, Cachexia drug therapy, Cachexia pathology, Heart Diseases drug therapy, Heart Diseases pathology, Humans, Molecular Targeted Therapy, Muscle, Skeletal pathology, Muscular Atrophy drug therapy, Muscular Atrophy pathology, Signal Transduction, Angiotensin II metabolism, Cachexia metabolism, Heart Diseases metabolism, Muscle, Skeletal metabolism, Muscular Atrophy metabolism
- Abstract
Cachexia is a serious complication of many chronic diseases, such as congestive heart failure (CHF) and chronic kidney disease (CKD). Many factors are involved in the development of cachexia, and there is increasing evidence that angiotensin II (Ang II), the main effector molecule of the renin-angiotensin system (RAS), plays an important role in this process. Patients with advanced CHF or CKD often have increased Ang II levels and cachexia, and angiotensin-converting enzyme (ACE) inhibitor treatment improves weight loss. In rodent models, an increase in systemic Ang II leads to weight loss through increased protein breakdown, reduced protein synthesis in skeletal muscle and decreased appetite. Ang II activates the ubiquitin-proteasome system via generation of reactive oxygen species and via inhibition of the insulin-like growth factor-1 signaling pathway. Furthermore, Ang II inhibits 5' AMP-activated protein kinase (AMPK) activity and disrupts normal energy balance. Ang II also increases cytokines and circulating hormones such as tumor necrosis factor-α, interleukin-6, serum amyloid-A, glucocorticoids and myostatin, which regulate muscle protein synthesis and degradation. Ang II acts on hypothalamic neurons to regulate orexigenic/anorexigenic neuropeptides, such as neuropeptide-Y, orexin and corticotropin-releasing hormone, leading to reduced appetite. Also, Ang II may regulate skeletal muscle regenerative processes. Several clinical studies have indicated that blockade of Ang II signaling via ACE inhibitors or Ang II type 1 receptor blockers prevents weight loss and improves muscle strength. Thus the RAS is a promising target for the treatment of muscle atrophy in patients with CHF and CKD. This article is part of a Directed Issue entitled: Molecular basis of muscle wasting., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
8. Angiotensin II, oxidative stress and skeletal muscle wasting.
- Author
-
Sukhanov S, Semprun-Prieto L, Yoshida T, Michael Tabony A, Higashi Y, Galvez S, and Delafontaine P
- Subjects
- Angiotensin II metabolism, Animals, Humans, Mice, Mitochondria, Muscle metabolism, Mitochondria, Muscle physiology, Muscular Atrophy physiopathology, NADPH Oxidases metabolism, Reactive Oxygen Species metabolism, Receptors, Angiotensin metabolism, Receptors, Angiotensin physiology, Angiotensin II physiology, Muscular Atrophy metabolism, Oxidative Stress physiology
- Abstract
Muscle atrophy (cachexia) is a muscle wasting syndrome associated with several pathological conditions in humans such as congestive heart failure, diabetes, AIDS, cancer and renal failure, and the presence of cachexia worsens outcome. Many of the conditions associated with cachexia are accompanied by stimulation of the renin-angiotensin system and elevation in angiotensin II (ang II) levels. Ang II infusion induces skeletal muscle atrophy in rodents and mechanisms include increased expression of the E3 ligases atrogin-1/MuRF-1, an elevated rate of ubiquitin-proteasome mediated proteolysis and increased reactive oxygen species (ROS) levels, closely mimicking conditions of human cachexia. Ang II-induced oxidative stress contributes to muscle atrophy in a mouse model. Nicotinamide adenine dinucleotide phosphate oxidase- and mitochondria-derived ROS contribute to ang II-induced oxidative stress. Specific targeting of ROS and nicotinamide adenine dinucleotide phosphate oxidase/mitochondria cross-talk could be a beneficial, novel therapy to treat cachexia.
- Published
- 2011
- Full Text
- View/download PDF
9. Angiotensin II induced catabolic effect and muscle atrophy are redox dependent.
- Author
-
Semprun-Prieto LC, Sukhanov S, Yoshida T, Rezk BM, Gonzalez-Villalobos RA, Vaughn C, Michael Tabony A, and Delafontaine P
- Subjects
- Animals, Male, Mice, Mice, Inbred C57BL, Mice, Mutant Strains, Muscle, Skeletal metabolism, Muscular Atrophy metabolism, NADPH Oxidases genetics, Oxidation-Reduction, Proteasome Endopeptidase Complex metabolism, Superoxides metabolism, Wasting Syndrome metabolism, Angiotensin II adverse effects, Muscle, Skeletal drug effects, Muscular Atrophy chemically induced, Reactive Oxygen Species metabolism, Wasting Syndrome chemically induced
- Abstract
Angiotensin II (Ang II) causes skeletal muscle wasting via an increase in muscle catabolism. To determine whether the wasting effects of Ang II were related to its ability to increase NADPH oxidase-derived reactive oxygen species (ROS) we infused wild-type C57BL/6J or p47(phox)(-/-) mice with vehicle or Ang II for 7days. Superoxide production was increased 2.4-fold in the skeletal muscle of Ang II infused mice, and this increase was prevented in p47(phox)(-/-) mice. Apocynin treatment prevented Ang II-induced superoxide production in skeletal muscle, consistent with Ang II increasing NADPH oxidase derived ROS. Ang II induced loss of body and skeletal muscle weight in C57BL/6J mice, whereas the reduction was significantly attenuated in p47(phox)(-/-) animals. The reduction of skeletal muscle weight caused by Ang II was associated with an increase of proteasome activity, and this increase was completely prevented in the skeletal muscle of p47(phox)(-/-) mice. In conclusion, Ang II-induced skeletal muscle wasting is in part dependent on NADPH oxidase derived ROS., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
10. The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension.
- Author
-
Kandavar R, Higashi Y, Chen W, Blackstock C, Vaughn C, Sukhanov S, Sander GE, Roffidal LE, Delafontaine P, and Giles TD
- Subjects
- Administration, Oral, Aged, Antihypertensive Agents administration & dosage, Antihypertensive Agents adverse effects, Antihypertensive Agents pharmacokinetics, Arginine metabolism, Dose-Response Relationship, Drug, Drug Monitoring, Endothelial Cells drug effects, Endothelial Cells metabolism, Female, Humans, Hypertension metabolism, Insulin-Like Growth Factor I metabolism, Male, Middle Aged, Nebivolol, Nitric Oxide Synthase antagonists & inhibitors, Nitric Oxide Synthase metabolism, Treatment Outcome, Arginine analogs & derivatives, Benzopyrans administration & dosage, Benzopyrans adverse effects, Benzopyrans pharmacokinetics, Blood Pressure drug effects, Ethanolamines administration & dosage, Ethanolamines adverse effects, Ethanolamines pharmacokinetics, Hypertension drug therapy, Metoprolol administration & dosage, Metoprolol adverse effects, Metoprolol pharmacokinetics
- Abstract
This study sought to determine if metoprolol succinate ER (MET), and nebivolol (NEB), a β1-AR with increased bioavailability of nitric oxide (NO), would have differing effects on plasma asymmetric dimethylarginine concentration in hypertensives. It was hypothesized that NEB, a β1-AR antagonist and β3-AR agonist with NO-releasing properties, and MET, only a β1-AR antagonist, would have different effects on plasma asymmetric dimethylarginine (ADMA) concentration. Forty-one hypertensive subjects randomly received either 50 mg of MET (n = 19) or 5 mg of NEB (n = 22) for 4 weeks followed by 100 mg MET and 10 mg NEB for 4 weeks. ADMA and insulin-like growth factor-1 (IGF-1) were measured by enzyme-linked immunosorbent assay kit; endothelial progenitor cells were estimated using fluorescein-labeled monoclonal antibody to KDR and CD133 receptors; arterial augmentation index was measured by radial tonometry. Baseline systolic/diastolic blood pressure was 155.1 ± 18.7/85.3 ± 12.5 mm Hg for MET subjects and 157.6 ± 20.7/87.1 ± 14.0 mm Hg for NEB subjects. Baseline ADMA was 0.32 ± 0.123 μmol/L in the MET group and 0.4035 ± 0.1378 in the NEB group. ADMA increased 44.78% and 72% in the MET group at weeks 4 and 8 (P < .05 for both), respectively, without increase in the NEB group. At week 8, augmentation index was increased in the MET group (P < .05). IGF-1 and endothelial progenitor cells were unchanged by treatment. Plasma ADMA and augmentation index are increased in a dose-dependent fashion by MET but not with NEB., (Copyright © 2011 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
11. Vitamin C and percutaneous coronary intervention.
- Author
-
Delafontaine P and Anwar A
- Subjects
- Angina Pectoris therapy, Antioxidants administration & dosage, Ascorbic Acid administration & dosage, Humans, Angina Pectoris drug therapy, Angioplasty, Balloon, Coronary, Antioxidants therapeutic use, Ascorbic Acid therapeutic use, Myocardial Reperfusion, Oxidative Stress drug effects
- Published
- 2010
- Full Text
- View/download PDF
12. Calcific constrictive pericarditis with refractory hypokalemia in a patient with Gitelman's syndrome.
- Author
-
Nachimuthu S, Balamuthusamy S, Irimpen A, and Delafontaine P
- Subjects
- Humans, Male, Middle Aged, Calcinosis etiology, Gitelman Syndrome complications, Hypokalemia etiology, Pericarditis, Constrictive etiology
- Abstract
Calcific constrictive pericarditis can be idiopathic or associated with radiation therapy, surgery, infection, or autoimmune disorders. Gitelman's syndrome is a distal renal tubular defect involving the thiazide-sensitive luminal sodium chloride cotransporter and has been associated with nephrolithiasis and chondrocalcinosis. There has not been any case of calcific constrictive pericarditis reported so far in association with Gitelman's syndrome. We have reported a male patient with persistent hypokalemia and refractory ascites diagnosed with calcific constrictive pericarditis and Gitelman's syndrome.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.